Search
Close this search box.

Adium Pharma reaches an important agreement with Moderna Inc. to collaborate in the distribution and commercialization of covid 19 vaccines in Latin America

Leading company in pharmaceutical innovation, headquartered in our country, signs an unprecedented agreement for the arrival of COVID-19 vaccines

Montevideo, Uruguay. February 21, 2022

ADIUM Pharma and Moderna Inc. reached an agreement for the distribution and commercialization throughout Latin America for SPIKEVAX, the vaccine developed by Moderna against SARS-CoV-2.

ADIUM is a leading pharmaceutical company that develops, produces and commercializes innovative high-quality products, and specializes in the therapeutic areas of oncology, cardiology, central nervous system, gynecology, among others. The company is headquartered in Montevideo, owns four pharmaceutical manufacturing sites in the region, with presence in Argentina, Bolivia, Brazil, Central America, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.

As part of the agreement, ADIUM will collaborate with Moderna in supply contract management with governments and currently in effect, and also continuous medical education, as well as the development of new agreements in countries where SPIKEVAX is not yet available.

“We are delighted to partner with Moderna to bring the COVID-19 vaccine to our Latin American population. Moderna is a leading company in the battle against the pandemic and we are proud to be partnered in this mission”, said Patricio Rodriguez, CEO of ADIUM.

“We are excited to collaborate with the target of increasing vaccination rates in Latin America, assisting patients, physicians, and governments in this effort. This alliance confirms our purpose to supply all Latin America with innovative treatments that contribute to improve the quality of life”, stated Rodríguez.

Moderna Inc., one of the largest growing pharmaceutical companies worldwide, specialized in research and development, has entrusted ADIUM to enable the arrival of the COVID 19 vaccine in Latin America, which has been developed with cutting edge technology (mRNA).

The RNA messenger platform (mRNA) is the starting point for the treatment of other severe diseases (cardiovascular, autoimmune, immuno-oncology, among others), under the sphere of investigation of Moderna Inc.

With this new agreement, Moderna Inc. is now another company that adds to the list of international research and development pharmaceutical companies that ADIUM has been representing within the region for more than twenty years.

ABOUT THE VACCINE
The Moderna vaccine against COVID-19 uses mRNA to provide a pattern for the cells to build a defense system in the organism against SARS‑CoV‑2, the virus that causes COVID‑19. The Moderna COVID-19 vaccine does not contain SARS‑CoV‑2 or any other virus, but the pattern that helps fight it off. ([i])

SPIKEVAX (also known as Moderna COVID-19 vaccine) is a vaccine that provides protection against COVID-19, and is indicated for people over 18 years of age. ([ii]) Recently, SPIKEVAX was granted temporary approval in Australia for over 12 years of age ([iii]).

The FDA has authorized Moderna’s COVID-19 vaccine for emergency use to prevent COVID-19 in people aged 18 years and older, in accordance with emergency use authorization, (EUA).([iv])

The European Commission has granted conditional marketing authorization (CMA) for the COVID-19 vaccine developed by Moderna, making it the second vaccine against COVID-19 authorized in the EU. ([iv])

About ADIUM:
It is a leading private pharmaceutical company in Latin America, headquartered in Montevideo, Uruguay. For the last 20 years, it has been a key and strategic partner for international research and development pharmaceutical companies in the commercialization of innovative and high technology products.

References

[i] https://www.modernatx.com/covid19vaccine-eua/recipients/es/moderna-vaccine

[ii] https://spikevax.com/

[iii] https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/moderna#approval-for-use-in-australia

[iv] https://ec.europa.eu/commission/presscorner/detail/es/ip_21_3

We use cookies on our website to provide you the most relevant experience by remembering your preferences and repeat visits. By Clicking "Accept", you agree to the use of all cookies.